Takeda Pharmaceutical Company Limited (TSE:4502) is unlikely to sell its over-the-counter (OTC) drug business even amid pressure to improve its finances as it closes a $59 billion takeover of London-listed Shire, Chief Executive Christophe Weber said. After the Shire deal, Takeda will have a stronger pipeline and be counted among the top 10 drugmakers by sales globally. But it will also become one of the world’s most indebted and has plans to sell up to $10 billion in non-core assets.